Janssen submits sNDA to FDA for Erleada in prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental New Drug Application to FDA seeking approval of a new indication for Erleada (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login